Clinical Trials | November 30, 2025
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
The receipt of this order further strengthens the company's position in the global pharmaceutical market
Most recently, Yuvraj was the Director of Operations, Business Development & Process Excellence at Zeon Lifesciences Ltd
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Subscribe To Our Newsletter & Stay Updated
